Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177095 · ClinicalTrials.gov registry record · Phase 4
Immune Monitoring to Facilitate Belatacept Monotherapy
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT04177095: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT04177095 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04177095, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
* To determine the utility of novel blood-based immune monitoring tools (Allosure and Trugraf) to facilitate belatacept monotherapy. * To determine the percent of belatacept-treated renal transplant patients that can be safely converted to belatacept monotherapy.
Interventions
- DIAGNOSTIC_TEST Allosure
- DRUG Immunosuppression reduction
- DIAGNOSTIC_TEST Trugraf
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177095
The ClinicalTrials.gov registry entry for NCT04177095 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Allosure is the first listed.
NCT04177095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177095 about?
NCT04177095 is a clinical study titled "Immune Monitoring to Facilitate Belatacept Monotherapy". * To determine the utility of novel blood-based immune monitoring tools (Allosure and Trugraf) to facilitate belatacept monotherapy. * To determine the percent of belatacept-treated renal transplant patients that can be safely converted to belatacept monotherapy.
What is the current status of trial NCT04177095?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2020-02-11. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04177095?
The interventions under investigation include: Allosure (DIAGNOSTIC_TEST), Immunosuppression reduction (DRUG), Trugraf (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04177095?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.